Aldosterone Production and Signaling Dysregulation in Obesity

Overview

Journal Curr Hypertens Rep

Specialty Cardiology & Vascular Diseases

Date 2016 Feb 4

PMID 26838033

Citations 23

Authors

Andrea Vecchiola

Carlos F Lagos

Cristian A Carvajal

Rene Baudrand

Carlos E Fardella

Affiliations

Soon will be listed here.

Abstract

In the past decades, we have extended the view of aldosterone effects beyond epithelial tissues. New evidence regarding the aldosterone/mineralocorticoid receptor (MR) pathway in active metabolic tissues, including adipose tissue, has confirmed its pathogenic role in systemic inflammation, endothelial dysfunction, insulin resistance, and dyslipidemia. Obesity, a current epidemic worldwide, increases aldosterone production by several adipocyte factors such as leptin but is also associated with local aldosterone production. In addition, obesity can modulate MR activation leading to signaling dysregulation and a pro-inflammatory profile of adipocytes. Current knowledge have deciphered that this phenotypical differences of obesity may be explained, at least in part, by novel non-genomic activation of MR, new inducers of aldosterone synthesis, and probably by several epigenetic modifications. In addition, with the understanding of the complex interplay of obesity, hormones, and receptors, targeted pharmacological therapy is expected and is currently under active research.

Citing Articles

Unveiling the Silent Danger of Childhood Obesity: Non-Invasive Biomarkers Such as Carotid Intima-Media Thickness, Arterial Stiffness Surrogate Markers, and Blood Pressure Are Useful in Detecting Early Vascular Alterations in Obese Children.

Mihuta M, Paul C, Borlea A, Roi C, Velea-Barta O, Mozos I Biomedicines. 2023; 11(7).

PMID: 37509481 PMC: 10376407. DOI: 10.3390/biomedicines11071841.

Cardiovascular Disease in Obstructive Sleep Apnea: Putative Contributions of Mineralocorticoid Receptors.

Badran M, Bender S, Gozal D Int J Mol Sci. 2023; 24(3).

PMID: 36768567 PMC: 9916750. DOI: 10.3390/ijms24032245.

Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists.

Mende C, Samarakoon R, Higgins P Am J Nephrol. 2023; 54(1-2):50-61.

PMID: 36682353 PMC: 10273909. DOI: 10.1159/000528783.

Primary aldosteronism and obstructive sleep apnea: What do we know thus far?.

Loh H, Sukor N Front Endocrinol (Lausanne). 2022; 13:976979.

PMID: 36246876 PMC: 9556954. DOI: 10.3389/fendo.2022.976979.

Development and Validation of a Nomogram-Based Prognostic Model to Predict High Blood Pressure in Children and Adolescents-Findings From 342,736 Individuals in China.

Liang J, Zhao Y, Chen Y, Huang S, Zhang S, Jiang N Front Cardiovasc Med. 2022; 9:884508.

PMID: 35811689 PMC: 9260112. DOI: 10.3389/fcvm.2022.884508.

References

Williams T, Monticone S, Urbanet R, Bertello C, Giraudo G, Vettor R . Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients. Mol Cell Endocrinol. 2012; 355(1):162-8. DOI: 10.1016/j.mce.2012.02.007. View

Fuller P, Young M . Mechanisms of mineralocorticoid action. Hypertension. 2005; 46(6):1227-35. DOI: 10.1161/01.HYP.0000193502.77417.17. View

Lifton R, Gharavi A, Geller D . Molecular mechanisms of human hypertension. Cell. 2001; 104(4):545-56. DOI: 10.1016/s0092-8674(01)00241-0. View

Vaidya A, Underwood P, Hopkins P, Jeunemaitre X, Ferri C, Williams G . Abnormal aldosterone physiology and cardiometabolic risk factors. Hypertension. 2013; 61(4):886-93. PMC: 3615445. DOI: 10.1161/HYPERTENSIONAHA.111.00662. View

Marcus Y, Shefer G, Sasson K, Kohen F, Limor R, Pappo O . Angiotensin 1-7 as means to prevent the metabolic syndrome: lessons from the fructose-fed rat model. Diabetes. 2012; 62(4):1121-30. PMC: 3609575. DOI: 10.2337/db12-0792. View

Carvajal C, Herrada A, Castillo C, Contreras F, Stehr C, Mosso L . Primary aldosteronism can alter peripheral levels of transforming growth factor beta and tumor necrosis factor alpha. J Endocrinol Invest. 2009; 32(9):759-65. DOI: 10.1007/BF03346533. View

Schuchard J, Winkler M, Stolting I, Schuster F, Vogt F, Barkhausen J . Lack of weight gain after angiotensin AT1 receptor blockade in diet-induced obesity is partly mediated by an angiotensin-(1-7)/Mas-dependent pathway. Br J Pharmacol. 2015; 172(15):3764-78. PMC: 4523334. DOI: 10.1111/bph.13172. View

Lim H, van den Brandt J, Fassnacht M, Allolio B, Herold M, Reichardt H . Silencing of the mineralocorticoid receptor by ribonucleic acid interference in transgenic rats disrupts endocrine homeostasis. Mol Endocrinol. 2008; 22(6):1304-11. PMC: 5419536. DOI: 10.1210/me.2007-0417. View

Caroccia B, Seccia T, Campos A, Gioco F, Kuppusamy M, Ceolotto G . GPER-1 and estrogen receptor-β ligands modulate aldosterone synthesis. Endocrinology. 2014; 155(11):4296-304. DOI: 10.1210/en.2014-1416. View

10.

Garg R, Hurwitz S, Williams G, Hopkins P, Adler G . Aldosterone production and insulin resistance in healthy adults. J Clin Endocrinol Metab. 2010; 95(4):1986-90. PMC: 2853992. DOI: 10.1210/jc.2009-2521. View

11.

Dooley R, Harvey B, Thomas W . Non-genomic actions of aldosterone: from receptors and signals to membrane targets. Mol Cell Endocrinol. 2011; 350(2):223-34. DOI: 10.1016/j.mce.2011.07.019. View

12.

Guo C, Ricchiuti V, Lian B, Yao T, Coutinho P, Romero J . Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation. 2008; 117(17):2253-61. PMC: 2746647. DOI: 10.1161/CIRCULATIONAHA.107.748640. View

13.

Schrier R . Aldosterone 'escape' vs 'breakthrough'. Nat Rev Nephrol. 2010; 6(2):61. DOI: 10.1038/nrneph.2009.228. View

14.

Luther J . Effects of aldosterone on insulin sensitivity and secretion. Steroids. 2014; 91:54-60. PMC: 4252580. DOI: 10.1016/j.steroids.2014.08.016. View

15.

Misra M . Obesity pharmacotherapy: current perspectives and future directions. Curr Cardiol Rev. 2012; 9(1):33-54. PMC: 3584306. DOI: 10.2174/157340313805076322. View

16.

Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M . Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2005; 91(2):454-9. DOI: 10.1210/jc.2005-1733. View

17.

Armani A, Cinti F, Marzolla V, Morgan J, Cranston G, Antelmi A . Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice. FASEB J. 2014; 28(8):3745-57. DOI: 10.1096/fj.13-245415. View

18.

Rickard A, Young M . Corticosteroid receptors, macrophages and cardiovascular disease. J Mol Endocrinol. 2009; 42(6):449-59. DOI: 10.1677/JME-08-0144. View

19.

Nedogoda S, Ledyaeva A, Chumachok E, Tsoma V, Mazina G, Salasyuk A . Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. Clin Drug Investig. 2013; 33(8):553-61. DOI: 10.1007/s40261-013-0094-9. View

20.

Ronzaud C, Loffing J, Bleich M, Gretz N, Grone H, Schutz G . Impairment of sodium balance in mice deficient in renal principal cell mineralocorticoid receptor. J Am Soc Nephrol. 2007; 18(6):1679-87. DOI: 10.1681/ASN.2006090975. View